The decision made by President Donald Trump’s administration is not to provide coverage for costly, highly sought-after items. obesity treatments as part of the federal government's Medicare initiative.
The Centers for Medicare and Medicaid Services announced late Friday that they will not provide coverage for these medications through Medicare’s Part D prescription drug benefit. Medicare primarily assists with healthcare costs for individuals aged 65 and over.
Trump’s predecessor, Joe Biden, proposed a rule In late November, following Trump’s re-election win, which was anticipated to prolong the coverage for medications such as Zepbound and Wegovy, a new regulation was set. This particular ruling wasn’t projected to become official until after Trump assumed his presidency again.
Trump resumed his position in Office in January. The Senate confirmed Dr. Mehmet Oz to head the Centers for Medicare and Medicaid Services on Thursday.
The CMS did not provide justification for their choice on Friday, and officials from the federal government did not promptly reply to inquiries seeking clarification.
President Trump’s Health and Human Services Secretary, Robert F. Kennedy Jr., has been a vocal critic of injectable medications that have surged in usage because of their potential for significantly reducing patient weight.
Polls show Americans favor Having Medicaid and Medicare cover the expenses. However, numerous insurance providers, employers, and other entities responsible for payments have been hesitant to foot the bills for these medications, which may be utilized. by a large segment of the population And this expense can amount to several hundred dollars per month.
Biden’s plan came at a steep price tag: It aimed to extend coverage to all Medicaid programs financed by state and federal funds for individuals with lower incomes, which could cost taxpayers up to $35 billion over the coming ten years.
Supporters of this coverage argue that addressing obesity could ultimately lower long-term expenses by decreasing the incidence of heart attacks and other costly health issues associated with the condition.
Mercer, the benefits consultant, has indicated that 44 percent of American firms employing 500 or more people provided coverage for weight loss medications in the previous year.
Medicare does cover medications such as Wegovy. for individuals with heart disease And they aim to lower their chances of experiencing further heart attacks, strokes, and other severe issues. Additionally, this federal initiative includes variations of these medications that help manage diabetes.
Over a dozen state Medicaid programs already provide coverage for weight-loss medications.
___
The Associated Press Health and Science Department is supported by the Howard Hughes Medical Institute’s Science and Educational Media Group along with the Robert Wood Johnson Foundation. However, the AP maintains full responsibility for the entirety of the content produced.
Tom Murphy, The Canadian Press